and human MSCs (hMSCs) have shown very promising results in animal models for multiple diseases due to their trophic and immunomodulatory activities. However, human clinical trials have not reached the success found in preclinical models. The general consensus is that, for most applications, we should increase the "therapeutic potency" of MSCs before translation into clinic. This goal can be achieved by increasing/improving the migration, engraftment, differentiation and immunomodulatory activities of the MSCs. The present article summarizes some of the approaches that use gene-modified MSCs (GM-MSC) for the treatment of different disorders. We will also discuss our experience using GM-MSCs expressing vasoactive intestinal peptide (VIP) for the treatment of multiple sclerosis.
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Gene transfer into MSCs to improve therapeutic efficacy
Most of the mechanism of action of MSCs are based on secreted factors 22) . In fact for some applications, the use of MSCs-conditioned media has a similar effect compared to the inoculation of MSCs 23, 24) . Therefore, improving/increasing the production of factors involved in its therapeutic activity should be an easy and effective way to increase its potency 25, 26) ( Improvement of the therapeutic efficacy of MSCs through genetic manipulation have also been pursued for Diabetes 34) , hindlimb ischemia, pulmonary hypertension 35, 36) , cardiomyocyte protection [37] [38] [39] , cerebral ischemia 40) , post-infarc- 64) Bone marrow-derived MSCs (human) Xenogenic IFN-β EAE Cobo M et al. 60) Adipose-derived MSCs (mice) Allogenic VIP EAE Payne NL et al. 65) Adipose-derived MSCs (human) Xenogenic IL-10 EAE Payne NL et al. 66) Adipose-derived MSCs (human) Xenogenic IL-4 EAE Mohajeri M et al. 67) Bone marrow-derived MSCs (human) Xenogenic FOXP3 EAE Lu Z et al. 68) Unknown (human) Xenogenic CNTF EAE Table 1 Gene-Cell Therapy approaches for the treatment of experimental autoimmune encephalomyelitis (EAE) using GM-MSCs tion myocardial repair 41, 42) , cartilage repair [43] [44] [45] and osteogenesis 46) .
MSCs expressing vasoactive intestinal peptide (VIP) for the treatment of multiple sclerosis
Multiple sclerosis (MS) is a severe, demyelinating disorder of the central nervous system (CNS). MS usually begins as a relapsing-remitting (RRMS) disease which in about 65% of the cases, develops into secondary-progressive MS (SPMS). RRMS is characterized by periods of acute disability followed by periods of functional recovery. However, the SPMS phase is characterized by a steady disease progression due to heavy axonal loss and neurodegeneration. In general, currently approved MS therapies (e.g. IFN-beta, glatiramer acetate and mitoxantrone), have shown good therapeutic benefit on RRMS but not on SPMS. In addition they are associated with side effects including depression, multifocal leukoencephalopathy and hypersensitivity reactions.
MSCs were initially thought to be a promising therapy of MS because of their ability to migrate into sites of inflammation, for its immunomodulatory activity and for its ability to enhance neurogenesis. However, although
MSCs demonstrated good therapeutic activity of MSCs on the EAE mouse model when treated at early stages 47, 48) , human trials were somehow disappointing [49] [50] [51] . Therefore, gene modifications of MSCs have been also pursued to increase their therapeutic potential for multiple sclerosis (see Table 1 ). We hypothesized that increasing the potency of MSCs through forced expression of VIP could be a good strategy. VIP is a neuropeptide of 28 amino acids with strong immunoregulatory (dampening T-cell responses and lowering inflammation) 52, 53) and neuroprotective activities (blocking microglial activation and induction of neuroprotective factors) 54) . Several authors have demonstrated important therapeutic effects of systemic delivery of synthetic VIP in several animal models of autoimmune diseases (Reviewed in 55)) including MS [56] [57] [58] .
In addition, a phase I/II clinical trial in patients with sarcoidosis demonstrated that inhalation of VIP decreased the levels of inflammatory markers in lung and increased the number of suppressive regulatory T-cells (Tregs) 59) .
We therefore generated MSCs/VIP using lentiviral vectors Special Issue (Mini Review) Gene-modified mesenchymal stromal cells for cell therapy that constitutively express the cDNA of VIP gene (Fig. 2) .
Injection of MSCs/VIP into mice with severe established disease ameliorated disease symptoms while unmodified
MSCs had no effect under the same conditions 60) . We will discuss this study in more detail to uncover some of the successes and failures of this approach.
1) Generation of MSCs secreting the bioactive form of VIP: Stability of expression
We routinely generated MSCs that stably secreted of 1-2 ng/ml of the fully processed 3.3kd VIP as detected by ELISA 60) . We could also achieve short term expression of up to 20-30ng/ml of VIP using higher MOIs of LentiVIP. However, MSCs do not have significant therapeutic activity when the disease progress toward a more aggressive phenotype [61] [62] [63] . We explored the therapeutic potential of MSCs/VIP and MSCs at peak of disease (complete paralysis of back legs and partial paralysis of front legs).
Only MSCs/VIP-treated mice recovered from complete hind leg paralysis toward a moderate hind leg paresis whereas the MSCs-treated mice developed a more aggressive disease. None of the MSCs/VIP treated mice required to be sacrificed, while 50%, and 70% of the mice treated with
MSCs and PBS respectively were sacrificed due to EAE severity 60) . It is also possible that the MSCs/VIP reached the CNS but their effect could only be detected during the first days after inoculation. New experiments are on-going in our laboratory to investigate this possibility.
3) Potential
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Conclusions Remark
Our experience using GM-MSCs for the treatment of EAE demonstrated that we can improve the therapeutic activity of MSCs without altering their main properties. Indeed, since the main therapeutic effects of MSCs are based on their inmunomodulatory activitity and the secretion of trophic factors, the over-expression of molecules having these effects endorses MSCs with a higher potency.
However there still too many unanswered question in terms of mechanism of action, migration potential and durability of the engraftment. In addition, we still must demonstrate that gene manipulation does not have any side effects on
MSCs, such as cell transformation. Once we can answer all these questions we will be in a position to translate GMMSCs into clinic. 
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